ACIRNA Therapeutics
PrivateLast Round
Series A
Mar 25, 2024
Total Funding Raised
$15.09M
Company Overview
ACIRNA Therapeutics operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Series A round in March 2024.
ACIRNA Therapeutics is a biotechnology research company that develops amplified circular RNA (acRNA) technology for precision RNA programming and immune-modifying therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ACIRNA Therapeutics Comparables
Compare ACIRNA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alaya.bio | 84% | |
| CREATE Medicines | 84% | |
| Able Sciences | 84% |
For institutional investors. Book with your work email.
ACIRNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 25, 2024 | ||||
| Grant | Feb 21, 2024 | ||||
| Debt | Nov 1, 2022 | ||||
| Seed | Feb 28, 2022 | ||||
| Accelerator | Jun 15, 2017 |
For institutional investors. Book with your work email.
ACIRNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Dreavent Capital | Seed, Series A |
| Alexandria Venture Investments | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 25, 2024
$13M round led by Dreavent Capital
- Feb 21, 2024
$300K raised from National Cancer Institute
For institutional investors. Book with your work email.
ACIRNA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ACIRNA Therapeutics's valuation, stock price, and market status.
Is ACIRNA Therapeutics a public or private company?
ACIRNA Therapeutics is a private company.
What is the current stock price of ACIRNA Therapeutics?
ACIRNA Therapeutics is a private company, so its shares have no public market price. Caplight tracks ACIRNA Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ACIRNA Therapeutics worth (valuation)?
Valuation information for ACIRNA Therapeutics is not publicly available.
Can I buy ACIRNA Therapeutics stock?
ACIRNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ACIRNA Therapeutics's last funding round?
ACIRNA Therapeutics's most recent funding round was Series A on March 25, 2024.
Who are the main investors in ACIRNA Therapeutics?
Key investors in ACIRNA Therapeutics include National Cancer Institute, Dreavent Capital, Alexandria Venture Investments.
Will ACIRNA Therapeutics IPO soon?
No public IPO plans have been announced for ACIRNA Therapeutics.
How can I track ACIRNA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ACIRNA Therapeutics's shares on secondary markets.